Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sol-Gel Technologies has announced positive results from encapsulated benzoyl peroxide (E-BPO) phase II trial conducted in the US.
Subscribe to our email newsletter
The drug developed by Sol-Gel, is used to treat mild-to-severe rosacea as well as acne.
The study demonstrated that 5% E-BPO provides a safe and effective treatment for rosacea.
Sol-Gel co-founder and CEO Alon Seri-Levy said the study results can change the way physicians treat rosacea.
"We plan to initiate Phase III studies for E-BPO next year," Seri-Levy added.
The double-blind, randomized, vehicle-controlled, dose-range study conducted at eight medical centers in the US on 92 rosacea patients for 12 weeks focused on identifying the lowest dose of E-BPO gel that demonstrates both safety and effectiveness to cure rosacea.
The study demonstrated that 53% of the patients treated with doses of 5% E-BPO achieved the primary success criteria compared to 20% of the vehicle control group.
Reduction in inflammatory lesion count was 69 % for the 5% E-BPO group compared to 33 % in the vehicle control group, according to the company.
Rosacea is a chronic and recurrent inflammatory dermatological disorder of unknown etiology commonly found in fair-skinned people of Celtic and northern European heritage.